These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
268 related items for PubMed ID: 19833407
21. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B, Di Loreto S. Neuroscience; 2005; 130(2):325-37. PubMed ID: 15664689 [Abstract] [Full Text] [Related]
22. Endocannabinoids in the immune system and cancer. Parolaro D, Massi P, Rubino T, Monti E. Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):319-32. PubMed ID: 12052046 [Abstract] [Full Text] [Related]
23. Pharmacology of cannabinoids. Grotenhermen F. Neuro Endocrinol Lett; 2004; 25(1-2):14-23. PubMed ID: 15159677 [Abstract] [Full Text] [Related]
24. Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. Alhamoruni A, Lee AC, Wright KL, Larvin M, O'Sullivan SE. J Pharmacol Exp Ther; 2010 Oct; 335(1):92-102. PubMed ID: 20592049 [Abstract] [Full Text] [Related]
25. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Martin BR. Life Sci; 2005 Aug 19; 77(14):1543-58. PubMed ID: 15949820 [Abstract] [Full Text] [Related]
26. CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. McAllister SD, Glass M. Prostaglandins Leukot Essent Fatty Acids; 2002 Aug 19; 66(2-3):161-71. PubMed ID: 12052033 [Abstract] [Full Text] [Related]
27. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA, Chapman V. Neuropharmacology; 2008 Jul 19; 55(1):85-93. PubMed ID: 18534634 [Abstract] [Full Text] [Related]
28. Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. Engler B, Freiman I, Urbanski M, Szabo B. J Pharmacol Exp Ther; 2006 Feb 19; 316(2):608-17. PubMed ID: 16214880 [Abstract] [Full Text] [Related]
29. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T. Br J Dermatol; 2004 Oct 19; 151(4):766-75. PubMed ID: 15491415 [Abstract] [Full Text] [Related]
30. Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARĪ±. Karwad MA, Couch DG, Wright KL, Tufarelli C, Larvin M, Lund J, O'Sullivan SE. Biochem Pharmacol; 2019 Oct 19; 168():465-472. PubMed ID: 31325449 [Abstract] [Full Text] [Related]
31. Molecular biology of cannabinoid receptors. Lutz B. Prostaglandins Leukot Essent Fatty Acids; 2002 Oct 19; 66(2-3):123-42. PubMed ID: 12052031 [Abstract] [Full Text] [Related]
32. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B. Arthritis Rheum; 2005 Mar 19; 52(3):759-69. PubMed ID: 15751073 [Abstract] [Full Text] [Related]
33. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Oz M. Pharmacol Ther; 2006 Jul 19; 111(1):114-44. PubMed ID: 16584786 [Abstract] [Full Text] [Related]
34. Role of endocannabinoids in cardiovascular shock. Malinowska B, Lupinski S, Godlewski G, Baranowska U, Schlicker E. J Physiol Pharmacol; 2008 Dec 19; 59 Suppl 8():91-107. PubMed ID: 19258666 [Abstract] [Full Text] [Related]
35. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V. Int Rev Neurobiol; 2009 Dec 19; 85():57-72. PubMed ID: 19607961 [Abstract] [Full Text] [Related]
36. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Gervois P, Fruchart JC, Staels B. Nat Clin Pract Endocrinol Metab; 2007 Feb 19; 3(2):145-56. PubMed ID: 17237841 [Abstract] [Full Text] [Related]
37. Endocannabinoids, adipose tissue and lipid metabolism. Pagano C, Rossato M, Vettor R. J Neuroendocrinol; 2008 May 19; 20 Suppl 1():124-9. PubMed ID: 18426511 [Abstract] [Full Text] [Related]
38. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Trends Pharmacol Sci; 2009 Oct 19; 30(10):515-27. PubMed ID: 19729208 [Abstract] [Full Text] [Related]
39. Cannabinoids and the immune system: an overview. Tanasescu R, Constantinescu CS. Immunobiology; 2010 Aug 19; 215(8):588-97. PubMed ID: 20153077 [Abstract] [Full Text] [Related]
40. The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease. Tanasescu R, Gran B, Constantinescu CS. Amino Acids; 2013 Jul 19; 45(1):95-112. PubMed ID: 22367605 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]